Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very pathetic of that guy. he always gave a rare example, ran long and seemingly useful introductory, and always came up with a negative conclusion at the end against nwbo.
any average Joe on the street can google and come up with ten times more of the cases with completely different outcome versus the rare case he cited.
the fact is that FDA will follow its ADCOM recommendation 95% of the times, and yet he cited one case where FDA went against it, to combat NWBO. LOL
how about you should have listened to him around early this year when the price hovered around $0.14-$0.19 and sold all?
because according to him, this company would have long gone out of business.
Exactly
Doubt it flipper since Linda has not issued 10Q yet and she must have known the unblinded results which prohibits her from making a financing deal without proper disclosure.
[Also Linda has had enough cash to last for six months. Only warrant exercising based on OS share count changes in the last month or so has put approximately ten-twenty million into the coffer of nwbo]
According to AVII himself/herself, he/she admitted he/she is an amateur having no proper professional credentials whatever in doing any credible biomed analyses.
As far as I know, he/she has gone astray since his/her investing in a Canadian biotech company called Biomira which later moved to the US and changed its name as Oncothyreon (ONTY) with heavy losses more than 15 years ago.
He/she has also said in the past his/her daughter might have suffered some kind of medical malpractice that had driven him/her in the studies and research of some biomed issues of his/her interests, including FDA related practice, etc., which is the only thing he/she has my respect in general.
But anyone can see from checking his/her posting history on NWBO, he/she has always magnified negative issues, real or imagined, while ignoring, downplaying any positive effects. According to him/her and the other usual few bears in this board, NWBO should have long gone out of business with a failed trial and no further financial lifeline.
His/her appearance has always been a sign of desperation of those who hate NWBO!
Yes, I have since put him/her in ignore.
Bio I think you have made a lot of nonsense recently on this topic. Ander is right, Maverick is right, and anyone who has been a biotech investor pretty much know this. I don't know why you are so full of it and rigid. Nobody is talking about a grey area where the trial results can be interpreted either way.
Assuming NWBO had failed its primary endpoint in its DCVax-L trial, nobody would have no doubt the company will notify the public in a timely manner, not waiting a month or more in a sec filing or hiding it somewhere in a Q report, because the market would act significantly negatively the moment the news is known or leaked, which itself warrants an imminent disclosure, because Linda cannot guarantee other persons in the know even only a few would not leak. At least you realize it's a good practice to disclose negative material news in a timely manner (in essence, it doesn't matter it is four days or three days, but definitely not much longer than that).
Since we all know DCVax-L trial will meet its primary endpoint. It's really hard to understand why you are so keen and sticky to any opportunity to "debunk" anyone who believe no news is good news at this point, more than 70-days after data lock.
I know sometimes people get taken away from debate per se. For me, this topic is done. I would not engage further.
Thanks VikingInvest. I intended to post as minimally as possible. I am a very simple man in life, not really keen to participate things most like.
This seems to confirm I have more than 3 posts allowed. Great. Sometimes I do need it.
The adjudicated is the second secondary endpoint, "the The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221."
[unbelievable did I count my allowable post wrong today?]
ATLnsider I appreciate dearly you putting your DD into a very vivid table for any ones to see how the primary endpoint will be readily met, and in general your valuable contribution.
Just like you to ponder meeting all the endpoints may not be a super good thing. For example, if DCVax-L is indeed very effective, it may bring about a very strong immunogenic reaction, i.e., there may have been indeed lots of pseudoprogression.
As a result, the third secondary endpoint, "The third secondary endpoint, PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221," may not be met or should not be met without adjudication.
There may also be other interwoven, interactive, somewhat conflicting effects as well, not really necessary meaning it will be a super good thing to have all endpoints met.
Simply put, there are many combinations to show DCVax-L is indeed both very safe and effective vaccine.
This is my last post for today. GLTA long!
you have my respect thermoo, but there are probably multiple actors here in this round of negotiation.
At least as you said, there is no buying from you guys which itself may give the bad actors "some encouragement."
Nonetheless for me, I don't care either way. I am waiting for TLD, and then commercial success.
Thank you for your reply and honesty.
Would warrant holders buy shares when they are negotiating for their warrants to be extended, hoping to have the new warrants if any priced as low as possible? -- not probable
Would warrant holders take no actions or short (sell) shares when they are negotiating for their warrants to be extended, hoping to have the new warrants if any priced as low as possible? -- probable even though it's illegal.
And there you have this softness in share price or steady but slightly eroding share price.
Will tomorrow be brighter -- definitely yes. I might join marzan in a buying mood again.
Full professor
Never heard any professor called each other full professor
That said, it's no problem people want to have shares at at prices as low as possible, but it's totally something else that people resort to FUDs in trying to get
It says something about the persons.
Using this criteria, 80% of all posters and 99% of all newbies can be put into the category of ignore.
It saves a lot of time to read useless, pathetic posts.
[unlike some, I do believe the delay of TLD has more or less something to do with FDA sorting out things, which is of course unusual at this stage, and the outcome will decide the trial results are either good or super good. the clue is that the initial primary and secondary endpoints are not discarded but included in the new reordered endpoints]
A tiny few retails who always knee jerking, one or two MMs jumped on preying as no big fish swims in the pristine still water
then you get stagnation
Or no more
A few thousand shares buying raised the price by a huge few pennies, and then a few hundreds pulled it right down to the line
It's time to do routines or watch human nature unfolding while sipping wine, tea or anything that can be sipped
Your choice?
Nonsense. Actually it's hard to believe NWBO after 14-years of DCVax-L PIII trial and numerous major rounds of communications with FDA has not been in a rolling BLA submission to FDA.
Yes the document when done could be one or two millions of pages, but it's utterly naive to think that NWBO can only start writing it after TLD and/or from scratch. It's reasonable out of the presumed million of pages, 85% may have been written which may require no additions, changes or inputs.
When I was invited to give a lecture in Columbia U in 2002, I was asked by a student what was the "trick" for me to have written and published 4 peer-reviewed journal papers and 6 conference papers in 3.5-years of my PhD studies (most students took an average of about 5 years in my school and published about 2 papers at that time), I said well I had various modules and templates ready to use and I only needed to make revisions and additions to the modules with new critical analyses and thinking based on new data/findings and then came up with appropriate conclusions.
For a typical BLA, it may contain the following major parts:
"A BLA must contain the following information:
– Form FDA 356h (cover sheet)– Applicant information
– Product/manufacturing information
• Source material / raw materials
• Manufacturing process and controls
• Formulation
• Facility information
• Contamination / cross-contamination information
• Environmental assessment or categorical exclusion
– Safety, efficacy and use
• Pre-clinical studies
• Clinical studies
•Labeling
from https://www.fda.gov/media/77755/download "
So as you can see, most contents can be readily written and probably have already been written. When TLD is ready and detailed analyses of the data are available, the rest of BLA document can be prepared, and revisions and additions can be made to the already written part wherever and whenever necessary and appropriate, which is not to say the preparation of BLA is not a huge task, but to say in definite term that NWBO cannot undertake such a task or NWBO has not undertaken a rolling BLA is equally arbitary.
BTW, Les' mention of submitting a BLA to UK authority by the end of this year may be an exaggeration, but certainly is not impossible.
Judged by the hiring spree not yet happened on the eve of commercializing DACVax-L and multiple clinical trials...
The preferred forced conversion...
Warrant extention...
The average age of key executives...
No regard to retail mood changes, daily inquiries, ...
No regard to filing, SEC,....
Linda concentrated all duties ....
[Flaskwork acquisition...
Options given out or being given out to employees, consultants ...]
Delayed everything...
A buyout is in waiting
And it takes time!
And yes I like lump sum payment.
[the jumpy retails, traders, flip floppers deserve what they deserve]
Exactly sukus. that's a rudimentary question.
In regards to stock price, I think we are holding well absent of news as there is almost daily addition to the share outstanding. It's perfectly understandable for anyone who wants to exercise and lock some profit, but the available warrants/options are dwelling as day goes by.
I have sold other stocks I had held for a long time and bought additional nwbo shares at many time points recently, left only a few stocks intended for tax loss to compensate a potential huge gain from nwbo (multiple millions at least) when I deem it's time to lock profit.
And if necessary I have six figure dry powder I can easily make ready for further disposal in a minute.
All are well despite restless impatience I seldomly experienced occasionally, but definitely no foul word unlike many, and afterwards only more determination.
Hope all are well with you and yours.
[It seems Linda has been taking time to get this done kind of once for all hating to see huge up and down instability as she is the largest share holder. So in her position I would also try my best to get all the ducks aligned, not give out fragmentary pieces of news. It may pleasantly surprise all of us when news get finally ready to release. It would be the best for us long to have one day seeing the price at higher single digit or even teen, instead of tormented on how many shares should be sold at what price if we see steady increase of price from here]
thermoo, as you understand but many not, the mass and the mainstream Wall Street are usually dumb enough which is normal, and waiting for a trumpeter to blow the charge sound, which in this case is positive TLD.
And it is as it has been written on the wall, but the dumb masses would want something written in a news release which would explicitly say both primary and key secondary endpoints have been met.
Yes, the primary endpoint has been met pending news release based on the released blinded data and the best-of-care (standard-of-care) which has shown quite consistent and stable results in treating GMB, i.e., it has not changed much for a decade, let alone it would be abnormal enough to over-live DCVax-L treated patients; and the results of any ECAs known today.
When you have a blended arm of about 300 patients which has about 20% of all patients lived more than five years compared to about 5% of the standard-of-care (placebo) patients, it's a signal of efficacy for key secondary endpoints to be met statistically significantly as well.
As for what has delayed that trumpeter to blow the charge sound yet, the only logic conclusion is for certainty, additional home run, or simply a procedural issue.
I am a small fish compared to you guys. I think it's time for you guys (Linda's friendlies) to band together to protect the interests of this company in which we all have heavily invested.
The 2nd Annual Glioblastoma Drug Development Summit
December 8-10
Virtual Event | 9am-5pm EST
Linda Liau
Chair of Neurosurgery
UCLA
Day One
Wednesday, December 09, 2020
10:20 am | Optimize the Role of Immunotherapy for Treatment of Glioblastoma
Day Two
Thursday, December 10, 2020
11:00 am | PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase
https://glioblastoma-drugdevelopment.com/about/speakers/
[this is a repost. Credit is due to the first poster in this board]
And you were saying you sold your cvm shares and bought nwbo?. Instead maybe you should do the opposite and post more in cvm board?
It may not be big deal though tomorrow Dr. Linda Liau will speak on how to Optimize the Role of Immunotherapy for Treatment of Glioblastoma at around 10:20am.
For that, traders will swarm and make the share price up some today, and for that and to tease these incoming traders I would buy shares to dump onto them just for fun?
wonderful thing would not just happen overnight, and patience is easy to say than done.
now chasing traders and flip flopper for fun
And yes all this maybe a reason why stock price has been up and down a little within the channel for a month or so because of the discussion of warrant extension. During this process, these in the know (have been in contact by Les for extension) have had the intention to suppress the price so whatever extra shares they get from agreeing on the extension they can get their exercise price as low as possible.
Judged by the price we have seen, the exercise price may be slightly above $2 this time around.
Make no mistake though the whole saga is very bullish, and the price will break out up after the deal is complete if not earlier in expectation of TLD.
The market is pretending it doesn't like the news (some warrant holders extend their warrants confirmed by Sentiment via conversation with DI). By pretending, I mean they shorted the stock to make that impression absent support of any Linda friendly hedge friends.
And the market may perceive there will not be any imminent TLD announcement because of extensions.
Traders would have sold, so would some retail investors disappointed with the extension based on the seemingly "logic" implication there will not be imminent TLD announcement.
In the meanwhile all forget another Linda is having a presentation talking about optimization in a few days; and if Linda P is a strategist, and now finally cares about share price, it's no better time to announce TLD imminently or at least before X-day.
this is my last post. Have a good day!
I don't feel that way but I do feel Linda has no true friends who can protect their positions, ie to maintain share price. Honestly it's not their fault, just they are too small hedge funds lacking resources.
The friendlies of the warrant holders and Linda and Les are a bunch of selfish, greedy persons. In most time, they are enemy of share prices: one as you very well expressed, and two the company seems to have forgotten its fiduciary duty to all share holders as if they were afraid of promoting its own company, and this situation has lasted since in the fall 2015.
Linda and the gang (friendly warrant holders) are holding together for an eventuality which I happen to believe it is aligned with my interest.
So I wait, wait, and wait while adding shares anytime as I deem appropriate.
But honestly I prefer this game ends ASAP, even though I feel it will be better when all are clear in a later time.
Today's selling is peanut as usual in such occasion with pathetic volumes, saying a lot about Linda's friends who are small balls.
A quiet period or silent period if self declared by a company would not last longer than usually two months
So prepared for TLD at any time this month, probably before 15 Dec if no further extension of warrants is announced.
So be appreciated the company's PR guy has told many that the company has been in a quiet period.
It will end soon and with big positive surprise!
this is my last post for today. Thanks and GL!
Thanks a lot. So the information is up to the date. They are small team, three or four persons actually who are doing the work on behalf of the company.
They need to deal with statisticians, steering committee, advisory board, independent KOLs, RAs (particularly FDA) at this everything is nothing but Covid vaccine period.
They may aim not only a home run, maybe two (nGBM and rGMB), but also other important issues.
It's easy to release TLD as it is available which would be at least one month ago, but it's better to resolve all the quires, possibilities, any unclear/contradictory data sets if existing before releasing TLD.
And they are also dealing with journal publication, warrant holders (Linda herself is a big part of it), maybe some buyout, partnership inquires or negotiation.
Based on what we have known and have expressed in this board repeatedly, I am quite certain we will at least get some kind of approval of DCVax-L for commercial use.
Like TD trader, and some others, I am all in as well. For the life of investing, sometimes one has to go against the rule of thumb, ie, the so-called diversification.
When did you send your inquiry and when did you get his (this) response from him?
The content of the response is what I would expect if he ever reply to inquiry at this so-called quiet period.
Remember he also said "we are working hard to deliver" based on his other reply to other poster (or you?) revealed in this board the other day.
Waiting is tough, and I believe this time around waiting a bit longer is highly rewarding.
We will have big enough gap ups and maybe many gapup days in a row to completely get rid of those doubters and whiners.
I can imagine Linda will turn many into sour grapes as days go by, and I will drink wine freshly made from those grapes watching this board.
I am not a mean person just cannot wish iron could turn into steel in a sense/
Reading this board just for a few minutes I almost gave up: what a bunch of xxx!
Retail, retail, and retail what can I say about you, assuming you are innocent and genuine, not part of Fudster gang
Have yet to completed your Sherlock Holmes's work on whether the trial has failed or not or whether the trial will fail or not?
Haven't turned this century old page yet? Then, can you please draw a curve using the blinded, blended updated data of DCVax-L trial and the curves of the other three best comparable, contemporaneous trials who received standard of care therapy only. can you see DCVax-L's primary endpoint is met with ss?
Do you forget DCVax-L is also safe?
In the support of the effectiveness expressed by the ss met primary endpoint, if that's not enough, then there are other five secondary endpoints individually or in combination if also met ss, will you still have any doubt DCVax-L is both safe and effective?
And after you have seen DCVax-L as a whole will have triple or quadruple more patients living over five years compared to the SOC, will you still doubt DCVax-L is effective?
In effect, even without the support of any secondary endpoints being met ss which will be highly unlikely, there have been a large number of various data points from peripheral blood samples, etc collected during the trial process from al patients, which can point to the immunogenicity differences in favor of the treatment arm patents.
The question now you should ask is how successful the trial will be. If you still have not grasped this very basics on what we are as of today as an investor, really I have no further words on you.
Let me repeat buying any shares below $2 is no brainier!
That makes u wonder where have those Linda's friends financiers been, the biggers, the thermooos, etc.
It was said they are dozens
They don't have spare change to buy
Are they actually manipulators
I love this situation, a thinly traded stock without even a single so-called friend finance to support (maybe they are shorting to lock profit with extended warrants as hedge)
the end price at which I will sell will be much much higher than we would expected.
No big fish or shark yet onboard, bad for price now but good for price in the future!
Yes marzan I agree. Indeed the company should have enough money for at least next several months with the money already raised and the money from warrant exercising.
It seems there have been algorithm machines working to bring share price down slowly every days, absent of news, but people may not realize there will be algorithm machines kicking into action start buying shares. All these machines have their set own points for actions.
Anyhow I don't think the share price will go down any more further.
Thank you marzan for all you and your minions have done, and GL.
From one lesson the company has learned that when the company didn't meet its deadline, mostly assumed by retail investors or probably by the short, there came tens of thousands of angry emails/phone calls, let alone full page upon full page of grievance in ihub, etc.
They (the company) would never PR something they are intended to do or are currently doing, without knowing for certainly they will get it from FDA, etc., such as seeking approval of rGBM, not only nGBM.
Imagine, a PR will be released, we get FDA approval of nGBM -- share price ultimately goes to $10-$20
Imagine, taking a longer time and get more detail analyses and you have to wait for FDA comments, etc, a later PR will be released, we get FDA approvals of both nGBM and rGBM -- share price will eventually go to $30-$40.
In the meantime, some retails have been squeegeed out of the market while some get more shares of the company by adding;and yes a little more dilution may come in effect.
What outcome do you choose?
The above is just some educated speculation, the company is still within its deadline to announce TLD later this month or early Dec.
The point, one has to exercise patience and trust Linda Powers. She will do things correct and do it on behalf of herself and all other investors to the maximal interests of us all.
BTW, she is the largest share holder, isn't she?
Until it doesn't [but nothing wrong with it].
I am with you brother. My share counts only increase with days passing by, peaking each passing week.
For a usual small development stage biotech company with a binary event coming, I would normally sell enough so that I could play with house money. I have done that before, but not this time with this stock.
The reason, as I said repeatedly, is we are actually not faced with a binary event anymore since the adaptation of the endpoints were revealed in EU clinicaltrial registry, specifically UK and Germany.
Then based on the blinded, blended data and the subsequent uptrend updated data, it's obvious the primary endpoint is met;
With the knowledge we have known about this disease and its standard of care treatment and outcomes, as well as various numerous failed Phase 3 clinical trials and the FDA approved Optune device, it would be highly likely at least one key second endpoint out of the five second endpoints will be met, which will be a support enough for FDA approval based on both safety and efficacy.
Because the endpoints the statisticians and the company and its experts are analyzing are numerous and complex compared to that of a usual trial, and because Linda Powers is ambitious, capable who is not a normal CEO who would just take anything which can normally be given, we may see a big surprise when everything is settle.
It's tough to hold all the shares but selling some at around $1-$2 is just out of the question.
I noticed Jane Street Capital LLC has served as a MM recently. It used to swarm the ETFs in the past, wondering why it suddenly is interested in an OTC traded stock.
It seems it has quietly manipulate in order to collect shares when the stock has been experiencing a "quiet period."
Below is an interesting article of 2016 about Jane Street:
https://www.nytimes.com/2016/02/23/business/dealbook/a-new-breed-of-trader-on-wall-street-coders-with-a-phd.html
A New Breed of Trader on Wall Street: Coders With a Ph.D.
By Landon Thomas Jr.
Feb. 22, 2016
HOLLYWOOD, Fla. — The mood in the markets may be getting grimmer, but in the booming world of exchange-traded funds, people just want to party.
And so it was last month at the $2.8 trillion industry’s annual jamboree in South Florida, where 2,200 investment advisers and fund salesmen came together for three days of hard drinking and product pitching. Against a backdrop of New Orleans jazz bands and poolside schmooze-fests — some call it spring break for the E.T.F. crowd — one event stood out, though.
It was an invitation-only party (crabs, cocktails and a D.J. on a moonlit dock) thrown by Jane Street, a secretive E.T.F. trading firm that, after years of minting money in the shadows of Wall Street, is now pitching itself to some of the largest institutional investors in the world.
And the message was clear: Jane Street, which barely existed 15 years ago and now trades more than $1 trillion a year, was ready to take on the big boys.
Much of what Jane Street, which occupies two floors of an office building at the southern tip of Manhattan, does is not known. That is by design, as the firm deploys specialized trading strategies to capture arbitrage profits by buying and selling (using its own capital) large amounts of E.T.F. shares.
It’s a risky business.
As the popularity of E.T.F.s has soared — exchange-traded funds now account for a third of all publicly traded equities — the spreads, or margins, have narrowed substantially, making it harder to profit from the difference.
Unlock more free articles.
Create an account or log in
And in many cases, some of the most popular E.T.F.s track hard-to-trade securities like junk bonds, emerging-market stocks and a variety of derivative products, adding an extra layer of risk.
These dangers were brought home last August, when markets were rattled by China’s decision to devalue its currency; some of the largest E.T.F.s sank by 50 percent or more.
While traders at large investment banks watched their screens in horror, at Jane Street, a bunch of Harvard Ph.D.s wearing flip-flops, shorts and hoodies, swung into action with a wave of buy orders. By the end of the day, the E.T.F. shares had retraced their sharp falls.
Editors’ Picks
Snapshots of Daily Life in a Remote Region of Portugal
The Celebrity Gossip You Won’t Find in the Tabloids
John Belushi in Focus: What a New Film Gets Right and What It Misses
“It’s remarkable what they can do,” said Blair Hull, a founder of an electronic trading firm who relies on Jane Street to make a market for his recently started E.T.F. “If you look at who provides this kind of liquidity these days, it’s fewer and fewer firms.”
It is not only Jane Street, of course. Cantor Fitzgerald, the Knight Capital Group and the Susquehanna International Group have all capitalized on the E.T.F. explosion.
And as these firms have grown, so has the demand for a new breed of Wall Street trader — one who can build financial models and write computer code but who also has the guts to spot a market anomaly and bet big with the firm’s capital.
In a word, these are not your suit-and-tie bond and stock traders of yore, riding the commuter train into Manhattan. They are, instead, the pick of the global brain crop.
The Morning: Make sense of the day’s news and ideas. David Leonhardt and Times journalists guide you through what’s happening — and why it matters.
Here is a small sample of Jane Street’s main traders: Tao Wang (doctorate in philosophy and finance from the National University of Singapore), Min Zhu (master’s in chemistry, Columbia), Brett Harrison (master’s in computer science with a focus in artificial intelligence, Harvard) and Srihari Seshadri (bachelor’s in computer science, Carnegie Mellon).
For large asset management firms like BlackRock, Vanguard and Invesco, the business of rolling out one E.T.F. after another has become a major profit center. But in many ways, the real money is being made by the trading firms that specialize in making a market in these securities.
For example, Jane Street, which is privately held, has increased its shareholder’s equity, or net worth, to more than $1 billion today from $228 million in 2007.
That cash cushion handily surpasses what such established investment banks as Evercore, Moelis and Greenhill have (as of 2014) as well as that at money management firms like Eaton Vance.
Moreover, it supports just 450 people in offices in New York, London and Hong Kong.
Jane Street was founded at the beginning of the previous decade, when a couple of option traders and a computer expert left Susquehanna to start their own business.
Harnessing Ph.D.-toting mathematicians to the most powerful computers money can buy has become the accepted way for hedge funds and banks to get a trading edge these days, but Jane Street takes this marriage of high tech and high intellect to a new level.
Writing computer code, or at the least being conversant in the firm’s program of choice, OCaml, is a requisite for all traders. Indeed, new traders must complete a monthlong OCaml boot camp before they start trading.
And to the degree that the super-shy Jane Street does have a public face, it belongs to its chief technology officer, Yaron Minsky, who gives frequent lectures at Harvard, M.I.T. and Carnegie Mellon, promoting the firm’s ability to manage risk by developing the best software around.
Caml TradingCredit...CreditVideo by Yaron Minsky
If Mr. Minsky is the spirit guide for Jane Street’s techies, Sandor Lehoczky, a past math Olympian and co-author of a book on problem-solving strategies for number whizzes, stands guard over the firm’s brain.
A star trader for the company, he also oversees its hiring process.
Jane Street has acquired a reputation for being perhaps the toughest interview in Silicon Valley and on Wall Street.
This is in part because the firm hires only a handful of new employees each year. To survive, candidates have to ace brain-twisting math riddles and game theory tests.
ImageMonish Shah of Mizuho at his desk, which has four computer screens. Exchange-traded funds now account for a third of all publicly traded equities.
Monish Shah of Mizuho at his desk, which has four computer screens. Exchange-traded funds now account for a third of all publicly traded equities.Credit...Cole Wilson for The New York Times
But as Mr. Lehoczky has said when asked what he is looking for in an E.T.F. trader, the ideal candidate possesses what he calls second-order knowledge — a form of intellectual humility in which really smart people can accept being wrong and own up to mistakes.
In that vein, a prospect might be fed a math problem that cannot be answered, just to gauge reaction to failure.
Because Jane Street finds itself competing more with Facebook and Google for talent than with, say, Goldman Sachs, the firm lays on the perks. These include a catered breakfast and lunch, a substantial gym right off the trading floor, generous child care benefits and an in-house speaker series that has featured the likes of Salman Rushdie, Christopher Hitchens and Garry Kasparov.
As for compensation, how much Jane Street’s rocket scientists get paid is as closely guarded a secret as its trading formulas. Still, it is apparently quite a bit.
“As a trader, if you do well, you will retire before you turn 30,” said one employee on an industry message board.
A number of larger banks, Goldman in particular, have been involved in exchange-traded funds for some time now, but the rest of the Wall Street banks are seeking to recruit their own E.T.F. hotshots.
One such trader is Monish Shah, a 31-year-old native of Mumbai, who was hired by the Japanese bank Mizuho to build a trading desk in its New York office.
Mr. Shah fits the profile of the up-and-coming E.T.F. trader: He is young, has a master’s degree in quantitative finance at Georgia Tech and is as much a writer of code as he is a trader.
On an old-school trading desk of mostly white men in their 50s buying and selling common stock, Mr. Shah stands out.
Ensconced at the far end of the firm’s equity desk, his four computer screens flash an array of color-coded execution cues, and he is a frequent target of good-natured trading-room banter, sending up his supersize console, his youth and even his Indian accent.
As stocks tumbled yet again on a Friday this month, curses rang out up and down the desk. An E.T.F. that Mr. Shah had been eyeing was down more than 3 percent, and now his color-coded signals were flashing green for buy — which is what he did, just as the market bell rang at 4 p.m.
Within a half-hour, the desk was empty as his colleagues rushed to catch the early train home. But Mr. Shah was not going anywhere; he had a business to build.
“There are so many moving parts; if just one thing goes wrong, you get killed,” Mr. Shah said, letting out a slow sigh. “So yes, it is stressful — but it is also my passion.”
Sub, I do think that's the case. For the SAP contains six endpoints, I think it's logic to conclude it's a compromise between the company and RAs because not company would like to have that numbers of endpoints.
So definitely I think the way we have six endpoints shows buying in of all RAs.
And because of that, it does need to take longer time than usual.
This stock will fly just with a little publicity from the company, which I think it's coming.
Nobody calls anybody full professor. It's really strange you called your self full professor the other day.
But at least you have a better understanding as to why TLD has been delayed buy not sure what you suggested is in your post.
Anyone should realize the trial now have one primary endpoint and five other secondary endpoints which unlike a usual trial which would normally have around three endpoints including primary endpoint.
So it should be understood DCVax-L trial should take longer time to analyze than a usual phase 3 trial.
Nothing abnormal is going on at this time, not definitely withholding data as you asserts.
Investors also don't understand if DCVax-L is truly very effective, then not all endpoints should be med. For instance, if patients reacts very positively to DCVax-L injection, then pseudo-progression would most likely occurs, then the second endpoint compares PFS between the treatment arm and the placebo arm would definitely not be met.
There is added complexity so it would take longer time than usual for statisticians, the company and experts to analyze the data.
For that reason, I don't see any delay at all, but it's about time if anything goes smoothly the TLD should be announced any day now.
Bio, I counted on a physical calendar using my index finger (it was due 14 Nov, and this Thursday 19 Nov with five day extension) . The point is we are not due yet for this Q report with extension, but why everybody said it was over due.
For such a simple fact easy to be verified by a simple google search, why people just said it was over due, which puzzle me!
As the general rule of thumb, "Companies must file their 10-Qs 40 or 45 days after the end of their quarters depending on the size of their public float." from https://www.investopedia.com/terms/1/10q.asp
Since NWBO's quarter ends on 30 September, its quarterly will be due on 14 Nov 2020, which is the day 45-day from 30 September.
So the company has time to release the Q later this week since it filed NT-10Q for five days of extension.
Too much FUDs from long today, and it seems most short takes a break. What a coincident?
For God's sake, if holding a few tens of thousand shares or a few hundreds of thousands of shares make you sleepless, sell enough before TLD if that makes you sleep better;
And the thinking of "but what are the chances our placebo group did better than expected," from a long, please give me a break!
In other trials with other indications, this had indeed happened repeatedly. To the knowledge of the SOC treatment for GBM and its outcomes, and the outcomes of numerous of clinical trials of various agents for GBM, none has indicated placebo (SOC) has had better outcome than the treatment, only exception I saw is with the result of CLDX Phase 3 trial. Nonetheless, in the trial, its placebo is not actually placebo and instead a proven active agent called KLH. In the case of NWBO, the placebo used is autologous PBMC which is known to be inactive substance compared to KLH.
Now what matters is that nwbo has run a lengthy trial and had five years of trial data for all patients, and as of 5 Oct, the trial has been locked for analyses.
What we have known are 1) its primary endpoint will be met, and it's highly likely at least some of its five other secondary endpoints will be met as well, which is enough for FDA approval.
Nobody in FDA in his/her right mind would not agree the above, particularly if more than triple or quadruple of patients in the trial can live five years than SOC patients!
EU approval is guaranteed with approved adapted endpoints, which at least warrants a price of $2-3 now; USA will follow. Even if FDA has not yet bought in with the adapted endpoints, it will be forced to approve with the convincing data.
We are all living in the public eye. FDA's own ADCOM if called upon will deal a huge blow to FDA, and FDA will have a convenient excuse to compromise -- agree to approve (this is of course a speculated worst case. I personally believe FDA like its EU counterpart has bought in the adapted endpoints. No reason why not.
Before the huge running up beginning a month ago, I said buying anything below $1 was no brainier; now I say buying anything below $2 is no brainier.
Facing TLD any day now, manipulation can only have a very short span of life.
Have to run for some errant. No time to spell check, or edit. Sorry for any inconvenience
Great, Good for you. I think investors being withholding now not buying more shares is because most want to see what is in the Q which should be out today or tomorrow. Normally, quarterly report of a developing stage biotech company is not beautiful, which is expected.
That's maybe we have not seen significant trading volumes in recent days, and people are "scared" to get in or add more.
When most investors think they are smart to wait after "not beautiful looking Q," it often surprises.
I don't care that much. Only thing I know is the share price will be substantially higher within a month time, if not tomorrow or within the next week.
This is my last post for today. GL
From the reading, it should be in parallel; otherwise I would use a then, or after. But it could be in serial as well. Even that, it should be very soon since the preparation alone would not take a long time versus submission, acceptance and publication. [If it's later in serial, then the results to be reported would be not only TLD, maybe much comprehensive and detail since the preparation of the publication has been done]
The company may report TLD any day now while it is still preparing the publication!
Regardless, share price at around 1.4 is very low considering what we have known about the trial, and its potential market values.